Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

EDG-7500

Small molecule · developed by Edgewise Therapeutics

Phase 2 Most advanced trial

EWTX Developer

2 Registered trials

What is EDG-7500?

EDG-7500 is an investigational small-molecule drug studied in Hypertrophic Cardiomyopathy, Healthy Volunteer.

At a glance

Drug type: Small molecule
Therapy area: Cardiovascular
Developer: Edgewise Therapeutics, Inc. (EWTX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06347159	Phase 2	Hypertrophic Cardiomyopathy	Active not recruiting	EWTX
NCT06738836	Phase 1	Healthy Volunteer	Completed	EWTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hypertrophic CardiomyopathyHealthy Volunteer

More from Edgewise Therapeutics

EDG-15400 Phase 2 Sevasemten Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the EWTX page.

Follow EWTX, the company behind EDG-7500

See EWTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EWTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z